Irinocan

Irinotecan, the active ingredient in Irinocan, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients, interfering with DNA replication in rapidly dividing tumor cells and providing a targeted chemotherapeutic approach.

GNH USA supplies Irinocan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinocan is used in the management of colorectal cancer, targeting metastatic disease.

Metastatic colorectal cancer: improves survival outcomes when incorporated into combination chemotherapy regimens.

Irinocan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Anemia: decreased red blood cell levels causing weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis: life‑threatening inflammation of the colon. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Hemorrhagic events: bleeding due to thrombocytopenia.

Before initiating Irinocan therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity throughout treatment. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia. - Assess liver function: check hepatic enzymes and bilirubin before each cycle. - Evaluate renal function: adjust therapy if creatinine clearance is impaired. - Use anti‑emetics prophylactically: reduce nausea and vomiting incidence. - Avoid concurrent strong CYP3A4 inhibitors: these may increase Irinotecan exposure. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Irinocan can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise Irinotecan plasma levels. - UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia. - Live vaccines: immunosuppression can reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase exposure. - Warfarin: Irinotecan may affect INR, requiring closer monitoring. - NSAIDs: combined use can heighten gastrointestinal toxicity.